pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,216 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints890BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7577Rare Disease1868Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • South Asian American families often keep autism diagnoses hidden, delaying care
    Child and adolescent psychiatrist Ritu Goel points out that the CDC now estimates autism affects about one in 31 U.S. children, a rise from earlier figures. She observes that many South Asian Ameri…
    STAT · 2mo agoNegative↗ source
  • Pediatrician urges rigorous trials for AI tools used with children
    Dr. Dua Hassan, a pediatrician at Boston Children’s Hospital, writes an opinion piece about the growing use of artificial-intelligence applications in child care. She describes a typical office vi…
    STAT · 2mo agoNeutral↗ source
← prev
page 66 of 89
next →
fda recalls67
fda medwatch60
fda press38
1164
Psychiatry & CNS866
Ophthalmology494
Pain478
Endocrinology & Metabolism473
Infectious Disease444
California law bans four harmful food additives, part of legislator Jesse Gabriel's push against ultra-processed foods
California Assemblymember Jesse Gabriel has become a prominent figure in state food policy, championing measures aimed at reducing the health risks of ultra-processed foods. In 2023 he introduced…
STAT · 2mo agoRegulatoryPositive↗ source
  • FDA approves Sanofi's teplizumab for children with stage 3 type 1 diabetes
    The FDA announced approval of teplizumab, a Sanofi developed therapy, for children aged 8 and older who have stage 3 type 1 diabetes. The decision came through the agency’s accelerated review path…
    STAT · 2mo agoApprovalPositive↗ source
  • WHO chief warns of worsening Ebola outbreak in DRC and Uganda after on-site visit
    The World Health Organization's director‑general said he is "really worried" after returning from a second trip to the Ebola‑affected regions of the Democratic Republic of the Congo and Uganda. He…
    STAT · 2mo agoNegative↗ source
  • 73-year-old woman begins medical residency, says she's all in
    In a recent First Opinion podcast, Dawn Zuidgeest-Craft, who is nearly 73, shared her decision to start a medical residency after completing medical school in her early seventies. The interview was…
    STAT · 2mo agoPositive↗ source
  • Prometheus secures $12 billion to develop artificial general engineers as biotech deals surge
    Prometheus announced a $12 billion capital raise aimed at building what it calls “artificial general engineers,” a new class of AI tools for biopharma research and development. Nonprofit Blood Can…
    STAT · 2mo agoDealPositive↗ source
  • Trump administration proposes rule to close Medicare drug price-negotiation loophole
    The White House announced a proposal to tighten a policy that stops drugmakers from sidestepping Medicare price negotiations by adding new active ingredients to existing products. The change would…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Engaging Religious Leaders Key to Containing Ebola in DRC and Uganda
    An opinion piece by Olivia Wilkinson and Katherine Marshall stresses that Ebola spreads through caring acts such as tending the sick and handling burials, and that mistrust and misinformation often…
    STAT · 2mo agoPositive↗ source
  • Rapport Therapeutics says it is ready to launch its seizure drug independently
    In a recent interview, CEO Abe Ceesay explained that Rapport Therapeutics has assembled an investor syndicate and feels fully prepared to bring its seizure drug to market on its own. Founded in 20…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Veteran researcher warns new OMB grant rule could politicize U.S. science
    David J. Skorton, president of the Association of American Medical Colleges, writes that after four decades in research he has never seen a threat to science like the new grantmaking rule being con…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Hospital finance leaders call for ending billing friction that drives high costs
    At the Healthcare Financial Management Association’s annual meeting in Maryland, hospital finance executives gathered to discuss the persistent problem of affordability in health care. While the hi…
    STAT · 2mo agoNegative↗ source
  • AstronauTx appoints Michelle Mellion as new chief medical officer
    STAT+ columnist Ed Silverman reports on the latest personnel moves in the pharmaceutical sector, a regular feature that tracks hires, promotions and departures. The most recent addition is Michell…
    STAT · 2mo agoPositive↗ source
  • ADA apologizes after expelling five experts for distributing editorial at diabetes conference
    At the American Diabetes Association's annual meeting in New Orleans, five diabetes researchers were expelled and warned they could be arrested after distributing paper copies of an editorial. The…
    STAT · 2mo agoNegative↗ source
  • Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
    Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued. The acquisition aims to pres…
    STAT · 2mo agoNeutral↗ source
  • RFK Jr.’s “Make America Healthy Again” pledge shows mixed progress, tracking successes and gaps
    STAT is monitoring the promises made by Robert F. Kennedy Jr. under his “Make America Healthy Again” agenda, cataloguing which goals have been met, which remain incomplete, and which have not been…
    STAT · 2mo agoNeutral↗ source
  • Chile releases new data on effectiveness of food warning labels
    Chile's health officials have released fresh data that assess how well the country's food warning label system works. The findings add to ongoing research about whether mandatory labels influence…
    STAT · 2mo agoNeutral↗ source
  • Federal probe finds private Medicare Advantage plans deny rehab care, then reverse on appeal
    A federal investigation has revealed that the nation's largest Medicare Advantage insurers routinely deny post-acute rehabilitative services to older and disabled beneficiaries. The review found t…
    STAT · 2mo agoRegulatoryNegative↗ source
  • J&J reports positive Phase 2/3 results for Imaavy in rare autoimmune anemia, paving way for label expansion
    Johnson & Johnson announced that its drug Imaavy, already approved for myasthenia gravis, produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia, a rare…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Takeda’s experimental TYK2 inhibitor zasocitinib outperforms Bristol Myers’ Sotyktu in psoriasis trial
    Takeda announced that its experimental TYK2 inhibitor zasocitinib showed statistical superiority over Bristol Myers Squibb’s approved psoriasis drug Sotyktu in a head‑to‑head study. The 16‑week tr…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Summit Therapeutics cancels $500 million secondary share offering citing market conditions
    Summit Therapeutics announced it would pull a planned $500 million secondary share sale just one day after the announcement, saying market conditions were unfavorable. The offering had been slated…
    BioPharma Dive · 2mo agoDealNegative↗ source
  • Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trial
    Novartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and funding
    Novartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…
    STAT · 2mo agoPositive↗ source
  • Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patients
    A targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…
    STAT · 2mo agoPositive readoutPositive↗ source
  • Synthetic lethality hype may spark new wave of biotech mergers
    The piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…
    STAT · 2mo agoPositive↗ source